S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:LEXX

Lexaria Bioscience (LEXX) Stock Price, News & Analysis

$2.21
-0.06 (-2.64%)
(As of 02/23/2024 ET)
Today's Range
$2.06
$2.25
50-Day Range
$1.24
$2.60
52-Week Range
$0.65
$3.60
Volume
93,345 shs
Average Volume
199,726 shs
Market Capitalization
$23.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

Lexaria Bioscience MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
9.5% Downside
$2.00 Price Target
Short Interest
Healthy
6.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.16mentions of Lexaria Bioscience in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.60) to ($0.51) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.57 out of 5 stars

Medical Sector

861st out of 939 stocks

Pharmaceutical Preparations Industry

405th out of 438 stocks


LEXX stock logo

About Lexaria Bioscience Stock (NASDAQ:LEXX)

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

LEXX Stock Price History

LEXX Stock News Headlines

Bill Gates is raving about WHAT?!
The legendary Microsoft founder says that this tech "will be as revolutionary as the personal computer." It could create a new generation of millionaire investors by the end of the decade. 
Bill Gates is raving about WHAT?!
The legendary Microsoft founder says that this tech "will be as revolutionary as the personal computer." It could create a new generation of millionaire investors by the end of the decade. 
Lexaria's Submits Investigational New Drug Application
LEXX’ Sweet Opportunity in GLP-1s
Lexaria Slides on New Drug Developments
Lexaria Bioscience files to sell 1.62M for its holders
See More Headlines
Receive LEXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/12/2024
Today
2/23/2024
Next Earnings (Estimated)
4/12/2024
Fiscal Year End
8/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LEXX
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$2.00
Low Stock Price Target
$2.00
Potential Upside/Downside
-9.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-6,660,000.00
Net Margins
-2,021.70%
Pretax Margin
-2,220.65%

Debt

Sales & Book Value

Annual Sales
$230,000.00
Book Value
$0.33 per share

Miscellaneous

Free Float
9,303,000
Market Cap
$23.07 million
Optionable
Not Optionable
Beta
0.45
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Christopher A. Bunka (Age 62)
    Chairman & CEO
    Comp: $291.19k
  • Mr. John M. Docherty M.Sc. (Age 55)
    President & Director
    Comp: $290.46k
  • Mr. Mike Shankman
    Chief Financial Officer
  • Kristin Hamilton
    Director of Operations
  • Vanessa Carle
    Head of Legal
  • Dr. Philip N. Ainslie Ph.D.
    Advisor & Consultant














LEXX Stock Analysis - Frequently Asked Questions

Should I buy or sell Lexaria Bioscience stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexaria Bioscience in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" LEXX shares.
View LEXX analyst ratings
or view top-rated stocks.

What is Lexaria Bioscience's stock price target for 2024?

1 equities research analysts have issued 12-month price objectives for Lexaria Bioscience's stock. Their LEXX share price targets range from $2.00 to $2.00. On average, they anticipate the company's stock price to reach $2.00 in the next year. This suggests that the stock has a possible downside of 9.5%.
View analysts price targets for LEXX
or view top-rated stocks among Wall Street analysts.

How have LEXX shares performed in 2024?

Lexaria Bioscience's stock was trading at $1.25 on January 1st, 2024. Since then, LEXX shares have increased by 76.8% and is now trading at $2.21.
View the best growth stocks for 2024 here
.

Are investors shorting Lexaria Bioscience?

Lexaria Bioscience saw a drop in short interest in January. As of January 31st, there was short interest totaling 592,800 shares, a drop of 10.5% from the January 15th total of 662,400 shares. Based on an average trading volume of 132,400 shares, the short-interest ratio is currently 4.5 days. Approximately 6.7% of the company's stock are short sold.
View Lexaria Bioscience's Short Interest
.

When is Lexaria Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 12th 2024.
View our LEXX earnings forecast
.

How were Lexaria Bioscience's earnings last quarter?

Lexaria Bioscience Corp. (NASDAQ:LEXX) issued its quarterly earnings results on Friday, January, 12th. The company reported ($0.13) EPS for the quarter. The firm had revenue of $0.15 million for the quarter. Lexaria Bioscience had a negative net margin of 2,021.70% and a negative trailing twelve-month return on equity of 165.37%.

Who are Lexaria Bioscience's major shareholders?

Lexaria Bioscience's stock is owned by many different institutional and retail investors. Top institutional shareholders include Invenomic Capital Management LP (7.01%), Cowen AND Company LLC (2.46%), Vanguard Group Inc. (0.44%) and Citadel Advisors LLC (0.28%).
View institutional ownership trends
.

How do I buy shares of Lexaria Bioscience?

Shares of LEXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LEXX) was last updated on 2/23/2024 by MarketBeat.com Staff